GlassScriptPhysician profile
Morales D Brown
NPI 1679775266
$3,068.89
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,115 · 2020: $1,335 · 2021: $325 · 2022: $87.59 · 2023: $22.33 · 2024: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $206.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $713.42 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $373.35 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $280.22 | 2019-2020 | |
| Abbvie INC. | $267.61 | 2021-2023 | Vraylar |
| Allergan, INC. | $228.60 | 2019-2020 | |
| Lundbeck LLC | $228.50 | 2019-2020 | |
| Alkermes, INC. | $228.34 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $199.18 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $180.32 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.43 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $95.15 | 2019-2020 | |
| Indivior INC. | $81.09 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.57 | 2020 | |
| Eisai INC. | $15.71 | 2020 | |
| Vertical Pharmaceuticals, LLC | $11.29 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morales Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.